{"id":52894,"date":"2023-04-07T01:44:13","date_gmt":"2023-04-07T01:44:13","guid":{"rendered":"https:\/\/dailytalks.org\/?p=52894"},"modified":"2023-04-07T01:44:13","modified_gmt":"2023-04-07T01:44:13","slug":"eisai-publishes-long-term-health-outcomes-using-simulation-model-of-lecanemab-using-phase-3-clarity-ad-data-in-peer-reviewed-neurology-and-therapy-journal","status":"publish","type":"post","link":"https:\/\/dailytalks.org\/?p=52894","title":{"rendered":"Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal"},"content":{"rendered":"<p>TOKYO, Apr 4, 2023 &#8211; (JCN Newswire) &#8211;  Eisai Co., Ltd. today announced an article about long-term health outcomes of anti-amyloid-beta (A\u03b2) protofibril* antibody lecanemab in people living with mild cognitive impairment (MCI) due to Alzheimer&#8217;s disease (AD) and mild AD (collectively known as early AD) using simulation modeling was published in the peer-reviewed journal Neurology and Therapy&#8230;<br \/><a href=\"https:\/\/www.jcnnewswire.com\/pressrelease\/82770\/3\/\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>TOKYO, Apr 4, 2023 &#8211; (JCN Newswire) &#8211; Eisai Co., Ltd. today announced an article<\/p>\n","protected":false},"author":1,"featured_media":52895,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[43],"tags":[],"class_list":["post-52894","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"featured_image_urls":{"full":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/04\/52894-eisai-publishes-long-term-health-outcomes-using-simulation-model-of-lecanemab-using-phase-3-clarity-ad-data-in-peer-reviewed-neurology-and-therapy-journal.jpg",240,144,false],"thumbnail":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/04\/52894-eisai-publishes-long-term-health-outcomes-using-simulation-model-of-lecanemab-using-phase-3-clarity-ad-data-in-peer-reviewed-neurology-and-therapy-journal-150x144.jpg",150,144,true],"medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/04\/52894-eisai-publishes-long-term-health-outcomes-using-simulation-model-of-lecanemab-using-phase-3-clarity-ad-data-in-peer-reviewed-neurology-and-therapy-journal.jpg",240,144,false],"medium_large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/04\/52894-eisai-publishes-long-term-health-outcomes-using-simulation-model-of-lecanemab-using-phase-3-clarity-ad-data-in-peer-reviewed-neurology-and-therapy-journal.jpg",240,144,false],"large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/04\/52894-eisai-publishes-long-term-health-outcomes-using-simulation-model-of-lecanemab-using-phase-3-clarity-ad-data-in-peer-reviewed-neurology-and-therapy-journal.jpg",240,144,false],"1536x1536":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/04\/52894-eisai-publishes-long-term-health-outcomes-using-simulation-model-of-lecanemab-using-phase-3-clarity-ad-data-in-peer-reviewed-neurology-and-therapy-journal.jpg",240,144,false],"2048x2048":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/04\/52894-eisai-publishes-long-term-health-outcomes-using-simulation-model-of-lecanemab-using-phase-3-clarity-ad-data-in-peer-reviewed-neurology-and-therapy-journal.jpg",240,144,false],"chromenews-featured":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/04\/52894-eisai-publishes-long-term-health-outcomes-using-simulation-model-of-lecanemab-using-phase-3-clarity-ad-data-in-peer-reviewed-neurology-and-therapy-journal.jpg",240,144,false],"chromenews-large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/04\/52894-eisai-publishes-long-term-health-outcomes-using-simulation-model-of-lecanemab-using-phase-3-clarity-ad-data-in-peer-reviewed-neurology-and-therapy-journal.jpg",240,144,false],"chromenews-medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/04\/52894-eisai-publishes-long-term-health-outcomes-using-simulation-model-of-lecanemab-using-phase-3-clarity-ad-data-in-peer-reviewed-neurology-and-therapy-journal.jpg",240,144,false]},"author_info":{"display_name":"Jonathan Jeriah","author_link":"https:\/\/dailytalks.org\/?author=1"},"category_info":"<a href=\"https:\/\/dailytalks.org\/?cat=43\" rel=\"category\">Health<\/a>","tag_info":"Health","comment_count":"0","_links":{"self":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/52894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52894"}],"version-history":[{"count":0,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/52894\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/media\/52895"}],"wp:attachment":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}